• 1
    Meltzer HY & Fang VS. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 1976; 33: 317324.
  • 2
    Gruen PH, Sachar EJ, Langer G, et al. Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry 1978; 35: 108116.
  • 3
    Kebabian JW & Calne DB. Multiple receptors for dopamine. Nature 1979; 277: 9396.
  • 4
    Beumont PJV, Harris GW, Carr PJ, et al. Some endocrine effects of phenothiazines: a preliminary report. J Psychosom Res 1972; 16: 297304.
  • 5
    Inoue H, Hazama H, Ogura C, Ichikawa M, Tamura T. Neuroendocrinological study of amenorrhea induced by antipsychotic drugs. Folia Psych Neurol 1980; 34: 181.
  • 6
    Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 1982; 170: 463467.
  • 7
    Weizman A, Maoz B, Treves I, Asher I, Ben-David M. Sulpiride-induced hyperprolactinemia and impotence in male psychiatric outpatients. Prog Neuro-Psychopharmacol Biol Psychiat 1985; 9: 193198.
  • 8
    De Rivera JL, Lal S, Ettigi P, Hontela S, Muller HF, Friesen HG. Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol (Oxf) 1976; 5: 273282.
  • 9
    Zanoboni A, Zanoboni-Muciaccia W, Zanussi C. Effects of sulpiride and l-dopa on prolactin secretion: comparison between men and women. Clin Pharmacol Ther 1977; 5: 531.
  • 10
    Kuruvilla A, Peedicayil J, Srikrishna G, Kuruvilla K, Kanagasabapathy AS. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 1992; 19: 603606.
  • 11
    Lal S. Growth hormone and schizophrenia. In Psychopharmacology: the Third Generation of Progress, ed Meltzer HY. New York: Raven Press, 1987: 809818.
  • 12
    Melkersson K, Hulting AL, Hall K. Hormonal evaluation in schizophrenic patients treated with neuroleptics. Neuroendocrin Lett 1999; 20: 199204.
  • 13
    Rosen T, Bosaeus I, Tölli J, Lindstedt G, Bengtsson BÅ. Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency. Clin Endocrinol 1993; 38: 6371.
  • 14
    Leysen JE. Receptors for neuroleptic drugs. Adv Hum Psychopharmacol 1984; 3: 315356.
  • 15
    Schwartz JC, Giros B, Martres MP, Sokoloff P. The dopamine receptor family: molecular biology and pharmacology. Semin Neurosci 1992; 4: 99108.
  • 16
    Dinan T. Comment. Growth hormone as a marker of central neurotransmitters in psychiatric illness. Current Medical Literature Growth and Growth Factors 1992; 7: 163165.
  • 17
    Yonkers KA, Kando JC, Cole JO, Blumenthal S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 1992; 149: 587595.
  • 18
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edn. Washington DC, American Psychiatric Association, 1994.
  • 19
    Södergård R, Bäckström T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperature. J Steroid Biochem 1982; 16: 801810.
  • 20
    Bang P, Eriksson U, Sara V, Wivall IL, Hall K. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: Improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh) 1991; 124: 620629.
  • 21
    Hilding A, Hall K, Wivall-Helleryd IL, Sääf M, Melin AL, Thoren M. Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19–82 years, in relation to those in healthy subjects. J Clin Endocrinol Metab 1999; 84: 20132019.
  • 22
    Labhart A. Classification of diabetes mellitus. In Clinical Endocrinology; Theory and Practice, eds. Thorn GW, Assal JP. Berlin, Germany: Springer-Verlag, 1986: 775777.
  • 23
    Tuninger E, Axelsson R, Levander S. A 3-year study of maintenance therapy with depot neuroleptics. Clinical characteristics and medication at study entry. Nord J Psychiatry 1994; 48: 409417.
  • 24
    Tuninger E. Depot neuroleptic maintenance treatment. Clinical, pharmacological and neuropsychological aspects. Dissertation, Lund, Sweden: University of Lund, 1997.
  • 25
    Hansen CE, Christensen TR, Elley J, Hansen LB, Kragh-Sørensen P. Clinical pharmacokinetic studies of perphenazine. Br J Clin Pharmacol 1976; 3: 915923.
  • 26
    Forsman A & Öhman R. Applied pharmacokinetics of haloperidol in man. Curr Ther Res 1977; 21: 396411.
  • 27
    Jørgensen A. Metabolism and pharmacokinetics of antipsychotic drugs. In Progress in Drug Metabolism, eds. Bridges JW, Chasseaud LF. New York, USA. Taylor & Francis, 1986: 111174.
  • 28
    Davis JM. Comparative doses and costs of antipsychotic medication. Arch Gen Psychiatry 1976; 33: 858861.
  • 29
    Nilsson LB. Determination of remoxipride in plasma and urine by reversed-phase column liquid chromatography. J Chromatogr 1990; 526: 139150.
  • 30
    Yasui N, Tybring G, Otani K, et al. Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients. Pharmacogenetics 1997; 7: 369374.
  • 31
    Llerena A, Alm C, Dahl ML, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 1992; 14: 9297.
  • 32
    Larsson M & Forsman A. A high-performance liquid chromatographic method for the assay of perphenazine and its dealkylated metabolite in serum after therapeutic doses. Ther Drug Monit 1983; 5: 225228.
  • 33
    Dahl ML, Ekqvist B, Widen J, Bertilsson L. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand 1991; 84: 99100.
  • 34
    Goldstein JM. Gender differences in the course of schizophrenia. Am J Psychiatry 1988; 145: 684689.
  • 35
    Chouinard G, Annable L, Steinberg S. A controlled clinical trial of fluspirilene, a long-acting injectable neuroleptic, in schizophrenic patients with acute exacerbation. J Clin Psychopharmacol 1986; 6: 2126.
  • 36
    Franks S. Regulation of prolactin secretion by oestrogens: physiological and pathological significance. Clin Sci 1983; 65: 457462.
  • 37
    Lal S & Nair NPV. Effect of neuroleptics on prolactin and growth hormone secretion in man. In Neuroactive Drugs in Endocrinology, ed Müller EE. North Holland: Elsevier, Biomedical Press, 1980: 223241.
  • 38
    Whalley LJ, Christie JE, Brown S, Arbuthnott GW. Schneider's first-rank symptoms of schizophrenia. Arch Gen Psychiatry 1984; 41: 10401043.
  • 39
    Meltzer HY, Kolakowska T, Fang VS, et al. Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Arch Gen Psychiatry 1984; 41: 512519.
  • 40
    Zemlan FP, Hirschowitz J, Garver DL. Relation of clinical symptoms to apomorphine-stimulated growth hormone release in mood-incongruent psychotic patients. Arch Gen Psychiatry 1986; 43: 11621167.
  • 41
    Bernstein JG. Psychotropic drug induced weight gain: mechanisms and management. Clin Neuropharmacol 1988; 11(Suppl 1): 194206.
  • 42
    Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995; 21: 463472.
  • 43
    Brady KT. Weight gain associated with psychotropic drugs. . South Med J 1989; 82::611617.
  • 44
    Stedman T & Welham J. The distribution of adipose tissue in female in-patients receiving psychotropic drugs. . Br J Psychiatry 1993; 162: 249250.